These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32798443)

  • 1. Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3.
    Macchi C; Greco MF; Botta M; Sperandeo P; Dongiovanni P; Valenti L; Cicero AFG; Borghi C; Lupo MG; Romeo S; Corsini A; Magni P; Ferri N; Ruscica M
    Am J Pathol; 2020 Nov; 190(11):2226-2236. PubMed ID: 32798443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
    Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
    J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ; Lambert G; Dullaart RP
    Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.
    Melone M; Wilsie L; Palyha O; Strack A; Rashid S
    J Am Coll Cardiol; 2012 May; 59(19):1697-705. PubMed ID: 22554600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
    Yang X; Zhang J; Chen L; Wu Q; Yu C
    Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.
    Hachem A; Hariri E; Saoud P; Lteif C; Lteif L; Welty F
    Curr Cardiol Rev; 2017; 13(4):274-282. PubMed ID: 28782494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
    Li Z; Liu Q
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1229-1235. PubMed ID: 29397939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice.
    Sui GG; Xiao HB; Lu XY; Sun ZL
    J Agric Food Chem; 2018 Aug; 66(34):8983-8990. PubMed ID: 30092639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
    Pirro M; Bianconi V; Francisci D; Schiaroli E; Bagaglia F; Sahebkar A; Baldelli F
    J Cell Mol Med; 2017 Dec; 21(12):3150-3161. PubMed ID: 28722331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
    Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
    J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.